Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -19.93 Million AUD | -57.24% |
| 2023 | -12.68 Million AUD | -10.55% |
| 2022 | -11.47 Million AUD | -52.46% |
| 2021 | -7.52 Million AUD | -13.13% |
| 2020 | -6.65 Million AUD | -40.49% |
| 2019 | -4.73 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -11.48 Million AUD | -100.0% |
| 2024 FY | -19.93 Million AUD | -57.24% |
| 2024 Q1 | -5.74 Million AUD | 17.95% |
| 2024 Q4 | -8.45 Million AUD | 0.0% |
| 2023 Q1 | -2.83 Million AUD | 47.8% |
| 2023 Q4 | -7 Million AUD | -100.0% |
| 2023 FY | -12.68 Million AUD | -10.55% |
| 2023 Q3 | -3.5 Million AUD | 38.36% |
| 2023 Q2 | -5.67 Million AUD | -100.0% |
| 2022 Q1 | -3.01 Million AUD | 43.54% |
| 2022 Q4 | -5.43 Million AUD | -100.0% |
| 2022 FY | -11.47 Million AUD | -52.46% |
| 2022 Q3 | -2.71 Million AUD | 54.9% |
| 2022 Q2 | -6.03 Million AUD | -100.0% |
| 2021 Q3 | -2.67 Million AUD | -22.29% |
| 2021 FY | -7.52 Million AUD | -13.13% |
| 2021 Q4 | -5.34 Million AUD | -100.0% |
| 2021 Q2 | -2.18 Million AUD | -100.0% |
| 2021 Q1 | -1.09 Million AUD | 0.0% |
| 2020 FY | -6.65 Million AUD | -40.49% |
| 2019 FY | -4.73 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Australian Clinical Labs Limited | 23.93 Million AUD | 183.306% |
| BCAL Diagnostics Limited | -6.4 Million AUD | -211.53% |
| Genetic Signatures Limited | -17.86 Million AUD | -11.625% |
| Genetic Technologies Limited | -12.01 Million AUD | -65.916% |
| Healius Limited | -645.8 Million AUD | 96.913% |
| Imagion Biosystems Limited | -12.47 Million AUD | -59.841% |
| Integral Diagnostics Limited | -60.69 Million AUD | 67.152% |
| INOVIQ Ltd | -6.55 Million AUD | -204.202% |
| Monash IVF Group Limited | -6.52 Million AUD | -205.477% |
| Rhythm Biosciences Limited | -6.85 Million AUD | -190.786% |
| Sonic Healthcare Limited | 511.09 Million AUD | 103.901% |